Eton Pharmaceuticals (NASDAQ:ETON) Trading Up 6% – What’s Next?

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) traded up 6% during mid-day trading on Thursday . The stock traded as high as $19.23 and last traded at $19.1750. 286,500 shares traded hands during mid-day trading, an increase of 7% from the average session volume of 268,070 shares. The stock had previously closed at $18.09.

Analyst Ratings Changes

ETON has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Thursday, January 22nd. Zacks Research raised Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Finally, HC Wainwright boosted their target price on shares of Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $31.00.

Eton Pharmaceuticals Trading Up 5.1%

The firm’s 50-day moving average is $16.26 and its 200 day moving average is $17.26. The firm has a market capitalization of $509.88 million, a price-to-earnings ratio of -76.04 and a beta of 1.19. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19.

Institutional Trading of Eton Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. State of Alaska Department of Revenue acquired a new stake in Eton Pharmaceuticals during the third quarter worth approximately $30,000. Ameritas Investment Partners Inc. bought a new position in shares of Eton Pharmaceuticals in the second quarter valued at $37,000. Quarry LP acquired a new position in Eton Pharmaceuticals during the 3rd quarter valued at about $37,000. Legal & General Group Plc purchased a new position in shares of Eton Pharmaceuticals during the second quarter valued at approximately $41,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth $44,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.